English
dalcetrapib
Sign in to saveDalcetrapib (INN, development code JTT-705) is a CETP inhibitor which was originally being developed by F. Hoffmann–La Roche until May 2012. DalCor Pharmaceuticals licensed dalcetrapib as a potential pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights into the development program, dalcetrapib is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome (ACS) and deliver superior cardiovascular outcome in a specific genetic subset of patients. A companion diagnostic test, developed
Research
266 papers- Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib.Clinical pharmacokinetics · 2018
- Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome.European heart journal · 2022
- Dalcetrapib: a review of Phase II data.Expert opinion on investigational drugs · 2010
- Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans.Journal of lipid research · 2023
- Effects of dalcetrapib in patients with a recent acute coronary syndrome.The New England journal of medicine · 2012
via PubMed
~4 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
{{Chembox | ImageFile = Dalcetrapib.svg | ImageSize = | IUPACName = S-[2-({[1-(2-Ethylbutyl)cyclohexyl]carbonyl}amino)phenyl]-2-methylpropanethioate | OtherNames =
| Section1 =
Excerpted from Wikipedia’s “dalcetrapib” article, available under the CC BY-SA 4.0 licence.